An abstract, to be presented at the ICML conference next week, indicates early signs of clinical effect with BI-1206. With five patients included so far, the recruitment seems to develop according to plan, why we expect the trial to roll over into Phase 2a in Q4 2019. More importantly, the abstract provides signs of clinical activity of BI-1206.